TGR-1202 and Ublituximab Show Promise in CLL - CLL Support
TGR-1202 and Ublituximab Show Promise in CLL
You need to be a member of this community to see this post.
Read more about...
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Drug Trial update - Gazyva with TGR-1202
Hi CLL friends,
I started my infusions Tuesday at OHSU in Oregon, no treatment prior. The first day
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
with-tgr-1202-tg-1101-the-pd-1-checkpoint-inhibitor-pembrolizumab-in-patients-with-advanced-cll...
flow cytometry is showing about 74% CLL involvement.
B-cell associated antigens CD19, CD20, CD22 and low intensity monoclonal surface immunoglobulin of...
FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study
trial exploring ublituximab (TG-1101, a chimeric recombinant glycoengineered monoclonal antibody...
Related Posts
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)- Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
More Promising BCL-2's and a Trial opportunity
Chemotherapy for CLL 
cll and Fenbendazole
